Cenobamate’s Real-World Impact: A New Hope for Focal Epilepsy?

IQVIA Holdings ((IQV)) announced an update on their ongoing clinical study.

Study Overview: The study titled Observational Cohort Study on Adult Patients With Not-adequately Controlled Focal-onset Seizures Treated With Cenobamate as Early Adjunctive Therapy in a Real-world Setting – FOCUS aims to evaluate the clinical response to cenobamate in adult patients with focal epilepsy in France, Germany, and Spain. The study is significant as it seeks to provide real-world data on the effectiveness of cenobamate for patients whose seizures are not adequately controlled by two or three anti-seizure medications (ASMs).

Intervention/Treatment: The intervention being tested is the drug Cenobamate, which is intended to treat adult patients with focal-onset seizures that are not adequately controlled by existing ASMs. The goal is to assess its effectiveness as an early adjunctive therapy.

Study Design: This is an observational cohort study with a prospective time perspective. It focuses on collecting real-world data from patients in a naturalistic setting, without any specific allocation or masking involved. The primary purpose is to observe the clinical outcomes of using cenobamate in the specified patient population.

Study Timeline: The study began on November 22, 2024, and the latest update was submitted on September 16, 2025. These dates are crucial as they indicate the study’s ongoing status and the most recent data collection efforts.

Market Implications: The ongoing study could influence investor sentiment positively if cenobamate demonstrates significant efficacy, potentially boosting the stock performance of Aziende Chimiche Riunite Angelini Francesco S.p.A and its collaborator, IQVIA. In the competitive landscape of epilepsy treatments, successful results could position cenobamate as a preferred option, impacting market dynamics.

The study is currently recruiting, with further details available on the ClinicalTrials portal.